Dermatology

Melanoma or skin cancer
#Dermatology #Francis Crick Institute #Gene therapy #Great Ormond Street Hospital #Melanoma #RNA

Silencing RNA causes moles to self-destruct in rare condition

UK researchers have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. The treatment could be used to reverse moles, and therefore prevent cancer. It could also potentially reverse other types of at-risk moles as an alternative to surgery. Read More

#News

Plaque Psoriasis
#Dermatology #Johnson & Johnson #Phase II trial #Plaque Psoriasis

J&J drug maintains skin clearance in plaque psoriasis for one year

Targeted oral peptide JNJ-2113 maintained skin clearance in moderate-to-severe plaque psoriasis (PsO) through one year in the Phase 2b FRONTIER 2 clinical trial extension, Johnson & Johnson (J&J) has reported. JNJ-2113 is the first and only investigational targeted oral peptide designed to block the IL-23 receptor. Read More

#News

Clinical trial
#Clinical trials #Dermatology #Johnson & Johnson #Plaque Psoriasis

J&J presents successful data from plaque psoriasis trial  

Johnson & Johnson has announced the first data from FRONTIER 2, the long-term extension of the Phase IIb FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only investigational targeted oral peptide designed to block the IL-23 receptor.  IL-23 plays a critical role in pathogenic T-cell activation… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

New DDW Highlights podcast: 19 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week our news highlights focus on skin conditions, with positive updates on hidradenitis… Read More

#News

#Biologics #Dermatology #Fibrotic disease #Immuno-dermatology #Monoclonal antibodies #Wound care

This week in drug discovery (12-16 February) 

News round-up for 12-16 February by DDW Digital Content Editor Diana Spencer. This week our news highlights focus on skin conditions, with positive updates on hidradenitis suppurativa, systemic sclerosis, wound-healing, and other dermatological conditions like atopic dermatitis and vitiligo. The top stories: Dual-action treatment… Read More

#News

Monoclonal antibodies
#Clinical trial #Dermatology #Monoclonal antibodies #Phase III trial #UCB

Monoclonal antibody improves hidradenitis suppurativa by 55%

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February). Emmanuel… Read More

#News

Scotland
#Biologics #Dermatology #Novartis #Scottish Medicines Consortium (SMC)

New biologic approved in Scotland for hidradenitis suppurativa

Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC). It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. The advice applies… Read More

#News #Regulatory

#Collaboration #Dermatology #Finance #Funding #Immuno-dermatology #Medicxi

$100M financing to advance immuno-dermatology pipeline 

Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. The company originates from the aggregation of six Medicxi companies.  Co-founded by Medicxi and several dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian… Read More

#Business & Investment #News

Janus kinase 1 protein
#Adverse event #Atopic dermatitis #Dermatology #JAK inhibitor #Korea #Pusan National University

Do JAK inhibitors increase the risk of serious adverse events?

South Korean researchers have found that the use of Janus kinase (JAK) inhibitors as a treatment for atopic dermatitis (AD) is not associated with a greater risk of serious adverse events. While several biologic treatment approaches have been proposed in the recent years for the treatment… Read More

#News

#Chronic kidney disease (CKD) #Dermatology #MC2 Therapeutics #Phase II trial

Potential breakthrough in treatment of urea associated skin diseases

MC2 Therapeutics has completed enrolment in its Phase II MC2-25 Ph2 chronic kidney disease-associated pruritus trial, with topline results expected in Q2 2024. MC2-25 CKD is a first-in-class drug candidate and could represent a potential breakthrough in the understanding and treatment of urea associated skin diseases. Read More

#News

Scleroderma
#Autoimmune disease #Certa Therapeutics #Clinical trial #Dermatology #Phase II trial

Scleroderma drug trial shows up to 60% improvement

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The results were presented at ACR Convergence 2023, the annual scientific meeting of the American College of Rheumatology in San Diego, California (10-15 November 2023). Treatment… Read More

#News

siRNA
#Biotechnology #Dermatology #Funding #Immuno-dermatology #siRNA

Is this a novel approach to immuno-dermatology? 

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi.  Pipeline  Under the leadership of Thibaud Portal, CEO of Aldena, the company’s goal is… Read More

#Business & Investment #News

Plaque psoriasis
#Bristol Myers Squibb #CHMP #Dermatology #European Medicines Agency #Phase III trial

First oral allosteric TYK2 inhibitor recommended in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.   Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor… Read More

#News #Regulatory

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

Listen now: Last episode of DDW Highlights for 2022

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting… Read More

#News

Epidermolysis bullosa patient has foot bandaged
#Clinical trial #Dermatology #Epidermolysis bullosa #Gene delivery #Gene therapy

‘Life-changing’ topical gene therapy gel heals EB wounds

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB).  People with dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. It’s an intensely painful condition, and medical treatment… Read More

#News #Trending News

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News